No quarterly revenue total was found in Dermata Therapeutics, Inc.'s SEC filings.
Dermata Therapeutics, Inc. (DRMA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$2.5 million.
Revenue
—
Net income
$-2.97M
-74.4% vs year-ago quarter
Operating cash flow
$-2.42M
+10.0% vs year-ago quarter
Free cash flow
$-2.53M
EPS
$-0.74
+55.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
4.02M
+490.1% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DRMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1853816
- Former names
- Dermata Therapeutics, Inc. (until Nov 2, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.0M | -$1.9M | -$1.9M | -$1.8M | -$1.8M |
| Net income | -$3.0M | -$1.8M | -$1.9M | -$1.7M | -$1.7M |
| Diluted EPS | -$0.74 | -$0.48 | -$1.65 | -$1.65 | -$1.66 |
| Operating cash flow | -$2.4M | -$2.5M | -$1.4M | -$1.8M | -$2.7M |
| Free cash flow | -$2.5M | — | — | — | — |
| Total assets | $5.3M | $7.5M | $7.9M | $5.1M | $6.6M |
| Total liabilities | $1.8M | $1.1M | $1.6M | $1.1M | $1.0M |
| Stockholders' equity | $3.5M | $6.4M | $6.2M | $4.0M | $5.6M |
| Cash and investments | $4.4M | $6.9M | $7.5M | $4.7M | $6.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 17, 2026 | Aug 16, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Other events
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 27, 2026 | May 27, 2026 |
All 371 Dermata Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.